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The injectable progestogens are not without problems. 
Over the short run, they disturb menstrual patterns in 
many women and cannot be immediately withdrawn if 
other problems arise . Over the long run, the return of 
fertility after discontinuation may be delayed, especially 
with Depo-Provera, 
Because of suspicions about other long -term effects, the 
use of Depo-Provera has been limited, In some countries 
concern about permanent infertility after injections has 
caused it to be restricted to older women with completed 
families , In other countries Depo-Provera has not yet won 
regulatory approval for general use. A controversy in the 
USA over the interpretation of statistical data on cervical 
carcinoma in situ has prevented approval specifically for 
contraception. The US Food and Drug Administration 
(USFDA) is reanalyzing the raw data on cervical carcinoma 
in situ, a possible precursor of invasive cancer. A report is 
expected in 1975, 
CONTENTS 
History . ...... . ... .. , ..... . ... .. .. .. ..... K- 2 

Mechanism of Action . . .. ... ... , .. . .. .. . , . K- 3 

Effectiveness . ... . .... .. . .. . , ... ... . . . ... K- 3 

Short-Term Side Effects .. . ... .. .. . ... . .. . K- 4 

Continuation .... . ....... , . ... , .. ... .... .. K- 7 

Fertility-Related Effects ... .. .. .. .. .. .. .. .. K- 8 

Debate over Cancer Risks. , . .... . . . ... .. .. K- 9 

Program Issues, ......... . ...... .. ..... .. K-11 

Distribution . .. , . ..... , . ....... . ' . .. ... .. .K-14 

Bibliography .. . ....... .. .. .. , . . ... . ... .. .K-14 

-Injectable Progestogens­

Officials Debate 

But Use Increases 

The place of the injectable progestogen in family planning 
remains uncertain. Although some compounds have been 
used as injectable contraceptives for over a decade and are 
both popular and effective, controversy still surrounds 
them , 
Depo-Provera ® (depot medroxyprogesterone acetate), a 
product of the Upjohn Company, USA, is currently the only 
injectable progestogen in widespread use; it is available 
commercially for contraceptive purposes in 64 countries, 
Another will be available soon , Schering AG of the Federal 
Republic of Germany is now registering an injectable 
progestogen, norethindrone enanthate (also known as 
norethisterone enanthate) in some 70 countries , It will be 
marketed commercially under the brand name Norigest ® 
and available for family planning organizations under the 
brand name Noristerat ®, 
Injectable progestogens offer many advantages that may 
be of special importance in developing countries, They are: 
• 	 highly effective in preventing pregnancy, on a par 
with oral contraceptives , 
• 	 independent of coitus , 
• 	 simple to administer, 
• 	 long-lasting, with injections required only two or 
four times a year, 
• 	 not lactation suppressors and thus, unlike combina­
tion oral contraceptives, can be offered to nursing 
mothers without danger of reducing the supply of 
milk, 
• 	 popular in developing countries where injections are 
associated with safe, effective, modern medicine, 
An estimated 1 million women now depend on injectable 
progestogens for contraception , That number is small com­
pared with the 50 million who use oral contraceptives and 
the 15 million who use intrauterine devices (IUDs), but the 
use of injectables appears to be gradually increasing. In 
recent years international donors of contraceptive supplies 
have received a growing number of requests for injectables 
and several countries have added Depo-Provera to their 
national family planning programs, 
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An injectable contraceptive is a welcome addition to family 
planning methods. But the present progestogen injec­
tables, troubled as they are by menstrual side effects and 
unresolved questions about long-term effects, have not yet 
won the unqualified approval of clinicians. Nevertheless, if 
further research can dispel fears about carcinogenicity and 
disprove or define the risk of infertility after Depo-Provera 
use, the injectable progestogens may yet become an 
important component of family planning programs, espe­
cially in areas where treatment by injection is popular. 
HISTORY 
The first systemic contraceptives, developed in the mid­
1950s, were Short-acting progestogens administered orally 
(128). With the development of longer-acting proges­
togens shortly thereafter, injectable contraceptives also 
became possible. Over the past 20 years a number of 
compounds have been tested as injectable contraceptives, 
but only one-Depo'-Provera-is currently being produced 
for international distribution and is widely used. In the 
USA, Depo-Provera has a checkered history of regulation 
and at present is not approved for contraception . 
The development of progestogens (synthetic compounds 
with the effects of the natural hormone progesterone) 
grew out of the post-World War II competition among drug 
companies to create synthetic hormones for a variety of 
therapeutic purposes. These early progestogens are me­
tabolized quickly and therefore have to be administered in 
frequent small doses in order to maintain their effect. As a 
result, when in the early 1950s Dr. Gregory Pincus and his 
associates set about utilizing the powerful ovulation­
inhibiting properties of these progestogens for fertility 
control, they concentrated on developing a contraceptive 
which could be administered orally . 
Dr. Karl Junkmann in 1953 discovered that esterifying a 
progestogen alcohol created a drug with long lasting 
effects when injected (20, 62). (Esters are formed from a 
free alcohol and an acid by the removal of water.) Junk­
mann and his associates synthesized esters of the proges­
togen norethindrone, including norethindrone enanthate, 
in 1958 (63) . Medroxyprogesterone acetate was developed 
by the Upjohn Company at about the same time (6). 
Schering AG began clinical studies of norethindrone enan­
thate (Norigest) in 1957. The major field trials of this drug 
were conducted in Peru, but other studies have taken 
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place in Egypt, Europe, and elsewhere. In 1967 Norigest 
was first marketed in Peru, but in 1971 it was withdrawn 
and field trials suspended pending further analysis of 
toxicologic findings in rats. Some researchers have since 
concluded that the findings in rats are not applicable to 
humans, and Schering AG is now registering Norigest in 
some 70 countries. The brand name Noristerat will be 
used when the drug is sold to international donor organi­
zations in order to make it readily identifiable if it should be 
diverted from intended channels (25). 
In 1958 the Upjohn Company began clinical trials of 
medroxyprogesterone acetate (Depo-Provera) as a treat­
ment for threatened or habitual abortion and for endome­
triosis. In 1960, the USFDA approved it for these uses on 
the basis of its safety, but without assessing its effective­
ness. In February 1974, after the agency concluded that 
Depo-Provera had not been proved effective for either of 
these uses and after steroids administered during preg­
nancy had been associated with congenital defects (69, 
117). the USFDA withdrew its approval for use of Depo­
Provera during pregnancy or to treat endometriosis (33, 
34, 35). 
The first clinical trials of Depo-Provera as a human contra­
ceptive began in 1963 and established a standard regimen 
of 150 mg every three months. Field trials began in 1965 
and have since been conducted in 61 countries (48). Since 
the late 1960s regimens of 300 or 400 mg every six 
months have also been studied. 
Upjohn applied to the USFDA in 1967 for permission to 
market Depo-Provera as a contraceptive in the USA (173), 
but, at first, questions about reversibility and relationship 
to breast cancer in beagle dogs and, more recently, ques­
tions about cervical carcinoma in situ in humans have 
blocked USFDA approval. 
In 1972 Depo-Provera received USFDA approval as a 
palliative treatment ofadvanced endometrial cancer. Cur­
rently this is the only approved use in the USA (168). Depo­
Provera has also been studied as a treatment for idiopathic 
precocious puberty (64, 83, 106), but its effectiveness and 
safety for this purpose have not been established. 
Several combinations of a progestogen and an estrogen 
are being distributed in a few countries as monthly injec­
tables . Promeco markets the combination of algestone 
acetophenide and estradiol enanthate in Mexico and Argen­
tina under the brand name Perlutal® and in Spain under 
the brand name Topasel®. In Chile, Recalcine Labora­
tories produces Aguria ®, and Silesia Laboratories 
produces Unalmes®. Both are combinations of dihy­
droxyprogesterone acetophenide and estradiol enanthate. 
Other steroids have also been tested as injectable contra­
ceptives, but are not being pursued because of the ex­
pense of clinical trials needed to prove safety (130) and / or 
the severe disturbances of the menstrual cycle which they 
produced (67, 74, 109). These other injectables include 
Deladroxate ®, developed by E. R. Squibb & Sons, USA, 
which was a combination of dihydroxyprogesterone aceto­
phenone and estradiol enanthate, for monthly injection; 
chlormadinone acetate, manufactured by E. Merck­
Darmstadt. FRG; and hydroxyprogesterone caproate, man­
ufactured by Schering as Prolutin Depot® and marketed by 
Squibb as Delalutin®. A few trials have also been con­
Fig. 1 . A woman receives an injection of Depo-Provera 
from a nurse at the McCormick Hospital Family Planning 
Clinic, Chiang Mai, Thailand . (Courtesy of Dr. E. B. 
McDaniel.) 
ducted combining Depo-Provera with estradiol cypionate 
(17, 78, 153), Norigest with estradiol undecylate (66). 
norgestrel with estradiol benzoate (21), and utilizing the 
estrogen estradiol undecylate alone (28, 67). 
Recent interest in progestogen-only contraceptives repre­
sents a return to the intentions of early researchers in 
steroidal contraception. They originally envisioned oral 
contraceptives as pure progestogens but then discovered 
that small amounts of estrogen, present as contaminants, 
reduced the breakthrough bleeding caused by the proges­
togens. As a result, manufacturers added controlled 
amounts of different estrogens to the pills (77). Estrogen, 
however, may cause annoying side effects such as nausea, 
dizziness, and breast tenderness (22) as well as other, 
more serious conditions (55) . To avoid estrogens, investi­
gators in the late 1960s turned their attention back to 
progestogen-only formulations-in the form of either oral 
"minipills" or injectables. 
MECHANISM OF ACTION 
The injectable progestogens prevent pregnancy in much 
the same way that combined oral contraceptives do, and 
with the same high degree of effectiveness, by 
• 	 inhibiting ovulation in many women 
• 	 increasing the viscosity of cervical mucus, thus 
forming a barrier to spermatozoa 
• 	 changing the rate of ovum transport through the 
oviducts 
• 	 making the. endometrium less suitable for implanta­
tion. 
The contraceptive effect of Depo-Provera depends primar­
ily on its ability to stop ovulation. Norigest works largely by 
altering cervical mucus (72, 74). After the first six to eight 
weeks, women using Norigest often do ovulate (4, 7, 73). 
The two injectables differ slightly in their effects, possibly 
because they are derived from different sources. Norethin­
drone enanthate, like most progestogens currently used in 
oral contraceptives, is derived from 19-nortestosterone, 
which is structurally similar to testosterone. Medroxypro­
gesterone acetate, on the other hand, is structurally simi ­
lar to progesterone. 
Progestogens probably affect ovulation by acting on the 
hypothalamus-pituitary axis, causing suppression of the 
surge of luteinizing hormone (LH) normally seen at mid­
cycle just prior to ovulation (38, 42, 74, 108, 112, 131, 
139, 161). Without that surge ovulation does not take place. 
The injectable progestogens make cervical mucus scant, 
viscous, and sticky, as it is during pregnancy and during 
the infertile late portion of the menstrual cycle (4, 29, 112, 
131, 184). This mucus interferes with the movement of 
sperm into the uterus. Post-coital tests have shown that 
some sperm penetrate the viscous cervical mucus but 
rarely reach the uterine cavity or the oviducts (29, 70, 71, 
181, 188). With Norigest changes in cervical mucus ap­
pear during the first month after the first injection (29) . 
With Depo-Provera, changes appear during the second 
month (30). 
Under progestogen contraception, the endometrium be­
comes unable to support a fertilized ovum. With Depo­
Provera, the endometrium takes on a resting or atrophic 
appearance which becomes more apparent as use contin­
ues (30, 112). With Norigest the effects vary. In some 
cases the endometrium resumes normal cyclic changes 
during the second month after an injection (20, 74) . In 
other cases it may remain unsuitable for implantation 
throughout Norigest use (4, 29). Both injectables also 
appear to cause changes in the oviducts, interfering with 
ovum transport and / or sperm capacitation and transport 
(12, 30, 184). 
EFFECTIVENESS 
The standard regimens of Depo-Provera and Norigest offer 
highly effective protection against pregnancy. Among 
Fig. 2. Advertisements for Depo-Provera in several 
languages reflect widespread use of the injectable. 
(Courtesy of the Upjohn Company.) 
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women receiving injections of 150 mg Depo-Provera at 
90-day intervals or 200 mg Norigest at 84-day (12-week) 
intervals, fewer than one in a hundred women are likely to 
become pregnant during a one-year period (see Tables 1 
and 2). The injectables are as effective in preventing 
pregnancy as combined estrogen-progestogen pills, 
slightly more effective than progestogen-only "minipills," 
and markedly more effective than IUDs. 
Data on the effectiveness of the 150 mg/3 month regimen 
of Depo-Provera shown in Table 1 represent over 20,000 
woman-years of experience with the drug . Less extensive 
studies using 300 or 400 mg Depo-Provera at six-month 
intervals have also been conducted (see Tables 1 and 2). 
There are not as many published studies of Norigest as of 
Depo-Provera (150 mg/ 3 months). but the pregnancy rates 
reported for women uSing Norigest appear to be slightly 
higher (see Table 1). With both drugs, most accidental 
pregnancies occur either shortly after the first injection, 
before the drug has fully taken effect, or just before the 
end of an injection interval when its effect has begun to 
wear off (74, 78, 81, 136). Some failures have also been 
attributed to injections which were not administered deep 
in the deltoid or gluteal muscle as required (186). 
SHORT-TERM SIDE EFFECTS 
Though highly effective and easy to administer, the inject­
able progestogens are not without problems. In the short 
Table 1-Effectiveness of Injectable Progestogen Contraceptives in Selected Studies, 1967-1975 
Reference Number of Number of Number of Method 
Author & Date of Publication Area 
Number Patients Woman-Months Pregnancies Failure Ratea 
Depo-Provera (150 mg/3 months) 
Apelo et al. 1974 3 Philippines 226 5,109 0 0 
Bloch 1971 9 South Africa 7,335 38,714 11 .35 
Brat 1971 11 Belgium 584 4,677 3 .77 
Chinnatamby 1971 16 Sri Lanka 1,000 18,261 3 .02 
Dodds 1971 23 Hong Kong 1,883 30,734 .04 
EI-Mahgoub etal. 1972 27 Egypt 231 4,671 0 0 
Koetsawang et al. 1974 81 Thailand 886 24,399 25 1.2 
Leiman 1972 87 South Africa 1,507 12,819 1 .09 
Linthorst et al. 1972 88 Netherlands 690 5,009 3 .n 
Mishell et al. 1971 b 111 USA 312 5,377 0 0 
Nunez 1970 122 Honduras 250 2,490 .48 
Powel! & Seymour 1971 129 USA 1,123 14,001 .09 
Schwallie & Assenzo 1973 150 USA & Latin America 3,857 72,215 15 .25 
Scutchfield et al. 1971 154 USA 650 4,958 .5 .23 
Soichet 1969b 157 USA 298 4,128 .29 
Tyler 1970b 166 USA 214 2,514 0 0 
Zanartu & Onetto 1972b 186 Chile 561 22,000 4 .25 
Zartman 1967b 189 USA 480 4,528 0 0 
Norigest (200 mg)C 
Chinnatamby 1971 15 Sri Lan ka 520 4,391 9 2.3 
EI-Mahgoub & Karim 1972 29 Egypt 171 4,329 0 0 
Kesseru-Koos et al. 1973 74 Peru 2,177 21,730 16 .88 
Koetsawang 1975 78 Thailand 71 648 8 14 .8 
Rice·Wray et al. 1971 136 Mexico 112 { l,069
d 
308 
0 
0 
0 
0 
Zanartu & Onetto 1972 186 Chile 130d 2,300 10 5.2 
Depo-Provera (6 months)e 
EI·Mahgoub et al. 1972 31 Egypt 92 904 0 0 
Khan et al. 1973 76 Pakistan 145 1,673.5 5 3.6 
Mackay et al. 1971 105 Austral ia 61 989 0 0 
Nunez 1971 123 Honduras 300 2,385 .5 
Schwallie & Assenzo 1972 149 USA & Latin America 991 21,470 31 1.73 
Zanartu & Onetto 1972 186 Chile 1,0991 43,387 54 1.4 
5989 20,387 28 1.6 
aCalculated by Pearl formula (pregnancies per 100 woman-years of usel. 

bParticipated in Upjohn cooperat;ve study . Data on all women (except Soichet 1969 (157),51 women) also reported by Schwallie & 

Assenza 1973 (150). 

clnJectlon Interval was 84 days except as noted d'njection interval was 90 days . eOose VIlas 300 mg except as noted. 

IDose was 250 mg. 90ata also reported by SchVllallie & A ssen zo 1972 (1491. 
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run, they frequently disturb menstrual patterns, some­
times severely, and Depo-Provera may also cause weight 
gain. 
Menstrual Cycle Disruptions 
All progestogens, but especially the injectables, disrupt 
menstrual patterns. Women using injectables may experi­
ence shorter or longer cycles, increased or decreased 
menstrual flow, and spotting . Many women tolerate these 
disturbances, but others do not . Menstrual disturbances 
cause more women to discontinue injectables than does 
any other side effect. Therefore, supplemental estrogens 
are sometimes used to regulate menstruation . 
The injectables have their most unpredictable effects on 
menstrual patterns during the first months of use. Dis­
cernible menstrual cycles may disappear entirely, to be 
replaced by intermittent bleeding and spotting of unpre­
dictable duration, interval, and rate of flow. If identifiable 
cycles continue, their length may vary widely from month 
to month and from one woman to another. In a few 
women, injectables immediately bring on amenorrhea. In 
many Depo-Provera studies fewer than half the users 
experienced "normal" menstrual flow following a first 
injection (2, 23, 81, 101. 149, 150). Irregular bleeding 
often gives way to amenorrhea which may then continue 
as long as the drug is used . By the end of two years, 40 
percent or more of Depo-Provera users may be amenor­
rheic (23, 81) (see Fig. 3). 
Researchers who have studied both injectables suggest 
that Norigest disturbs menstrual patterns less than Depo­
Provera (29, 74, 185). But comparing separate studies of 
the two injectables is difficult because of differing defini­
tions of normal menstrual patterns and differing methods 
of aggregating data. While more and more Depo-Provera 
users experience amenorrhea as usage continues, Nori­
gest users appear to experience an increasing proportion 
of normal cycles as time passes (29, 144) (see Fig. 4). This 
observation may be biased, however, by the fact that 
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Fig. 3. Percentages of women experiencing various 
bleeding patterns while receiving three-month injections 
of Depo-Provera (150 mg). 
SOURCE: Adapted from Koetsawang et al (81) 
women with disrupted menstrual patterns are more likely 
to abandon the method than are women with normal 
cycles. 
Management of Bleeding 
Orally administered estrogens are often used to treat 
menstrual disturbances caused by injectable progesto­
gens. At first the estrogens suppress menstrual bleeding . 
Then, when they are withdrawn and estrogen levels drop, 
withdrawal bleeding, which may be similar to normal 
menses, usually occurs. Thus, cyclic administration of 
estrogens can be used to treat excessive bleeding, irregu­
lar bleeding, or amenorrhea. 
Various estrogens have been used in different regimens, 
ranging from a full cycle of oral contraceptives (23) to a 
single 10 mg injection of long lasting (depot) estrogen (93, 
136) to 1 mg or less of oral estrogen daily for several days 
each month (9, 24, 29, 67, 84, 91, 101 , 122, 129, 136, 
154, 184). Supplemental estrogens have been adminis-
Table 2-Effectiveness of Depo-Provera in Selected Studies by Life Table Method l , 1972-1974 
Pregnancies per 100 women 
Author & Date Reference Number of Women 
of Publication Number Area Starting Use Year Year Year Year Year 
2 3 4 5 
THREE MONTH 
DOSE (150 mg) 
McDaniel et al. 
1974 
103 Thailand 9,284 In Each Year: 
Cumulative: 
1.0 
1.0 
.4 
1.4 
0 
1.4 
Schwallie & 
Assenzo 
1973 
150 USA & Latin 
America 
3,857 In Each Year : 
Cumulative 
.31 
.31 
.26 
.53 
.37 
.90 
0 
.90 
0 
.90 
Zanartu & Onetto 
1972 
186 Chile 561 In Each Year : 
Cumulative: 
.5 
.5 
.3 
.8 
0 
.8 
0 
.8 
SIX MONTH 
DOSE 
McDaniel & 
Pardthaisong 
1974 (400 mg) 
101 Thailand 1,132 In Each Year: 
Cumulative : 
.7 
.7 
.9 
1.6 
.8 
2 .4 
.2 
2.6 
.6 
3.2 
Schwallie & Assenzo 
1972 (300 mg) 
149 USA & Latin 
America 
991 In Each Year: 
Cumulative: 
2 .28 
2.28 
1.34 
3 .62 
1.06 
4.68 
.57 
5.25 
Zanartu & Onetto 
1972 (300 mg) 
186 Chile 598 In Each Year : 
Cumulative : 
1.8 
1.8 
1.3 
3.1 
1.2 
4 .3 
.6 
4.9 
lThe life table method measures pregnancy rates per 100 women in a specified time period of contraceptive use. 
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tered either routinely, in response to a patient's request or 
complaint, or when indicated by objective criteria such as 
heavy bleeding. McDaniel has suggested the following 
indications for the use of supplemental estrogens with 
Depo-Provera: 
• 	 prolonged spotting (more than 7 days in 28) 
• 	 heavy bleeding (more than was usual before injec­
tions began) 
• 	 more than 7 days bleeding 
• 	 any bleeding which is or could become a source of 
progressive anemia 
• 	 three or more months of amenorrhea, if it is disturb­
ing to the woman (91). 
Other conditions, such as pelvic infection, cervicitis, malig­
nancies. moniliasis, or tricomoniasis, may also produce 
menstrual disruption. Clinicians should therefore ensure 
that these conditions are absent before blaming the injec­
table (9). 
Although he has suggested specific indications for the use 
of supplemental estrogens, McDaniel himself administers 
them routinely to all his patients in the McCormick Hospi­
tal Family Planning Program in Chiang Mai Province, 
Thailand. He does so in an attempt to provide women with 
the reassurance of at least one withdrawal bleeding be­
tween injections and to prevent the rare occurrences of 
heavy bleeding which would require immediate medical 
care difficult to obtain in rural areas (52). 
If oral estrogens are used in conjunction with injectable 
progestogens, some women may consider the method not 
much more convenient than taking standard oral contra­
ceptives (24, 67). This objection may be largely overcome 
by the administration of a single dose of long acting oral 
estrogen, such as quinestrol. given monthly or at the time 
of injection, as is currently done in the McCormick Hospital 
program (94). Despite the fact that estrogens sometimes 
cause side effects such as nausea and dizziness, the 
advantages of a regular menstrual pattern outweigh the 
disadvantages of estrogenic side effects for some women 
(155). Also, the advantages of complete protection for a 
three-month interval may outweigh the apparent incon­
venience of using both oral medication and injections. Fur­
thermore, the woman who fails to take her oral estrogen 
supplement does not increase the risk of pregnancy as 
does the woman who fails to take an oral contraceptive 
tablet (24, 91). 
Several researchers have studied either Depo-Provera or 
Norigest combined with a long-lasting injectable (depot) 
estrogen-for example, 25 mg medroxyprogesterone ace­
tate with 5 mg estradiol cypionate (17, 78) or 50 mg 
norethindrone enanthate with 5 mg estradiol undecylate 
(66). These combination injectables, administered 
monthly, produce fewer menstrual pattern disturbances 
than the higher-dose, longer-lasting progestogens alone. 
No pregnancies have been reported with these combina­
tions, but experience is still very limited. 
Weight Gain 
Weight gain, which may be an advantage to some and a 
disadvantage to others, occurs ina majority of Depo­
Provera users (2,46. 87, 122, 141,155). In clinical studies 
mean weight gain has ranged from 1.4 pounds (141) to 9 
pounds (155) in the first year of Depo-Provera use. Some 
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Fig. 4. Percentages of menstrual cycles of various types 
in Peruvian Norigest users with previously normal men­
strual patterns, by year of Norigest use. 
SOURCE: Adapted from Schering AG (145). 
researchers find that weight gain levels off after the first 
year (15, 46, 190). Others report a slow and continuing 
increase (141, 150). McDaniel et al.. studying 800 Thai 
women who used Depo-Provera for 30 months, found that 
mean weight gain at the end of 12 months was 2.8 
pounds; at 24 months, 5.1 pounds; and at 30 months, 5.4 
pounds (103). Which women will be affected is not predic­
table, although obese wcmen may gain less than others 
(87). 
In some parts of the world weight gain is actually an asset 
(3, 16). Apelo et al. report from the Philippines that: 
Weight gain did not prove to be a problem because this was 
usually welcomed by most women, especially those who 
belonged to the lower socioeconomic group. A gain in 
weight, to them. connoted tolerance to the drug and they 
felt happy about it (3). 
Carbohydrate Mt;tabolism 
Depo-Provera may have some effect on carbohydrate 
metabolism, although this relationship has not been def­
initely established. Some researchers find that Depo­
Provera raises glucose levels in the blood (13, 39, 114, 
160); others report that it does not (30, 150, 165, 167, 
171 ). 
The clinical issue at stake in the debate over carbohydrate 
metabolism is whether diabetics and pre-diabetics should 
use Depo-Provera. If Depo-Provera does raise blood glu­
cose levels, diabetics and pre-diabetics may not be able to 
produce the additional insulin necessary to metabolize the 
extra glucose (39). Since diabetics and pre-diabetics face 
higher risks during pregnancy, their need for effective 
contraception is great. Close medical supervision during 
their use of contraception is necessary. 
Progestogen-only minipills do not seem to interfere with 
carbohydrate metabolism (133). No changes in carbohy­
drate metabolism have been reported in women using 
Norigest (29, 40, 184). 
Other Side Effects 
Other complaints reported by users of injectables include 
nausea, dizziness. headache, nervousness, chills, change 
in skin pigmentation, galactorrhea, painful menstruation, 
lessening of libido, diminished orgasm, and acne. How 
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often non menstrual side effects occur and what proportion 
of users experience these often highly subjective symp­
toms vary from one study to the next. In the Upjohn 
Company's cooperative studies of Depo-Provera, Schwal­
lie and Assenzo reported that nonmenstrual side effects 
other than weight gain were similar in type and frequency 
to those reported by users of oral contraceptives (149, 
150). On the other hand, Scutchfield and his associates 
found that, in a Georgia (USA) family planning clinic, the 
side effects among Depo-Provera users paralleled those of 
IUD users rather than those of orals users (154). Larranaga 
and Kesseru have commented that there are fewer non­
menstrual side effects with Norigest than with orals (86). 
Injectables might be expected to cause fewer nonmen­
strual side effects beca use they do not contain estrogen, 
which has been blamed for nausea, dizziness, and head­
ache associated with combination oral contraceptives (22). 
With the possible exception of weight gain in Depo­
Provera users, clinicians have not observed symptoms of 
metabolic or endocrine changes among users of injec­
tables. Most field trials have yielded no clinical evidence 
that the injectables adversely affect blood clotting, adrenal 
or liver function, blood pressure, or lactation, all of which 
are affected to some degree by estrogen-progestogen 
contraceptives. Nor have laboratory studies produced any 
conclusive evidence of adverse metabolic or endocrine 
effects. 
CONTINUATION 
Despite the side effects of injectables, 60 percent or more 
of all users can be expected to continue with the method 
for at least one year (see Table 3). Continuation rates are 
influenced not only by the characteristics of the contracep­
tive method but also by the age and parity of the user, 
social and cultural attitudes, accessibility of services, 
availability of alternate methods, and other factors. There­
fore, comparisons among studies are difficult to make. 
Researchers who have compared continuation rates for 
different contraceptive methods in similar patient popula­
tions have found that the continuation rate for Depo­
Provera was higher than that for orals but lower than that 
for IUDs (3,95,154) (see Fig. 5). Doctors at a clinic in Egypt 
report that the continuation rate for Norigest was higher 
there than rates both for IUDs and for orals (29). 
Among side effects of Depo-Provera, excessive and irregu­
lar menstrual bleeding or spotting can be blamed for the 
largest proportion of discontinuations-between one­
quarter and one-half of all first-year drop outs. Amenor­
rhea is responsible for about 10 percent of discontinua­
tions (see Table 4) . Menstrual disturbances caused by 
Norigest, because they are less severe than those due to 
Depo-Provera, apparently cause fewer discontinuations, 
though reports are few. In the Peruvian field trials of 
Norigest, by the end of two years 5.5 percent had dropped 
out because of menstrual disturbances, most of that in the 
first year. Some 87 women discontinued Norigest because 
of amenorrhea; 15, because of spotting or breakthrough 
bleeding (74). 
Women may find menstrual disturbances upsetting be­
cause they think that irregular or excessive bleeding is a 
symptom of sickness or that amenorrhea is a sign of 
pregnancy. Religious practices, folk beliefs, and rumors 
may also contribute to a woman's concern. For example, in 
Egypt, investigators have reported that : 
Table 3-Percentage of Women Continuing Use of Depo-Provera or Norigest by Months of Use in Selected Studies, 1970-1974 
Percentage of Women Receiving Next Injection 
Author & Date 
Reference 
Number 
Country 
Number of 
Women 
Dose I nterva I 
in Months 
by Months of Use 
3 6 9 12 15 18 24 36 48 60 
DEPO-PROVERA: 
Apelo er al. 1974 3 Phil ippines 226 3 92 81 72 63 60 
Dodds 1971 23 Hong Kong 1,883 3 61 48 
Khan et al. 1973 76 Pakistan 145 6 54 41 34 26 
Koetsawang et al. 81 Thailand 886 3 76 60 46 38 
1974 
McDan iel er al. 103 Thailand 9,284 3 74 59 48 
1974 
McDaniel & 101 Thailand 1,132 6 86 78 67 55 46 
Pardthaisong 1974 
McDaniel & 102 Thailand 217 3 79 69 64 60 
Pardthaisong 1973 108 6 69 60 
McDaniel & 95 Thailand 2,967 3 89 78 69 62 55 48 
Pardthaisong 1972 
Schwallie & 150 USA & Latin 3,857 3 59 42 30 24 22 
Assenzo 1973 America 
Schwallie & 149 USA & Latin 991 6 67 42 27 14 
Assenzo 1972 America 
Scutchfield 1971 154 USA 723 3 76 57 49 
Sin er al. 1973 156 Malaysia 550 1-6 63 41 
Zartman 1970 190 USA 478 3 93 77 
NORIGEST: 
Kesseru-Koos 74 Peru 1,844 84 days 86 75 69 66 
et al. 1973 
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For many women this unpredictable menstrual behavior 
was disturbing as they feared that amenorrhea may indi ­
cate pregnancy or they believe that retention of menstrual 
blood has a serious toxic effect on the body. Spotting is 
troublesome as it compels our cases to prohibit intercourse 
due to religious habits; mild or excessive bleeding is most 
alarming (67) 
Bantu women believe that amenorrhea means blood will 
collect in the head, causing headaches (68) . In Chiang Mai 
Province, Thailand, the rumor once circulated that amen­
orrhea leads to insanity (95). 
If such fears can be eliminated, many women will tolerate 
amenorrhea. That a woman's psychological well-being 
depends on regular menstruation may be, as Molitor puts 
it, "a somewhat masculine idea" ("une idee un peu 
masculine") (113). Poor nutrition and short birth intervals 
in developing countries may make regular menstrual 
patterns the exception rather than the rule . Clinicians from 
various areas report that many women actually are 
pleased by the absence of menstruation (81, 84, 113). 
Educating and reassuring women about menstrual dis­
turbances can promote continuation of the method. In 
Mexico, Rice -Wray and her associates 
have found that the continuation rate depends largely on 
the confidence the patient has in the doctor and the 
expla nation she received (136) . 
Zanartu, in Chile, has recommended group instruction 
about menstrual disturbances (186), and Chinnatamby, 
from Sri Lanka, has stressed the importance of repeated 
assurances (16). 
Among non menstrual side effects of Depo-Provera, weight 
gain is sometimes a reason for discontinuation, but, be­
cause the gain usually is moderate, it is not a major cause 
of dropouts. For example, in the Upjohn Company's coop­
erative studies, involving mainly US women, it caused only 
1.7 percent of the participants to discontinue (149). 
Various other nonmenstrual symptoms, including those 
subjectively determined, are responsible for a small pro­
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Fig. 5. Percentages of women continuing various contra­
ceptive methods in three clinic programs, 1971-1974. 
portion of discontinuations among users of injectables. 
Only 1.1 percent of the women in the Peruvian field trials 
abandoned Norigest because of nonmenstrual side effects 
(74). In most large studies of Depo-Provera, less than six 
percent discontinued because of nonmenstrual complaints 
other than weight gain (16, 81, 104, 149, 150). 
FERTILITY-RELATED EFFECTS 
Return of fertility may be delayed for several months or 
longer after discontinuing use of an injectable. This effect 
is more frequent and longer lasting with Depo-Provera 
than with Norigest. In addition, various progestogens may 
be associated w ith virilization and an increase in congeni­
tal defects among the offspring of women who receive the 
drugs during early pregnancy. 
Return of Fertility 
A study of 114 women who discontinued Depo-Provera in 
order to become pregnant showed that median time to 
Table 4-Percentage of Women Discontinuing Use of Depo-Provera for Menstrual Disturbances 
by Years of Use in Selected Studies, 1970-1973 
Percentage Discontinuing 
Author & Date 
of Publication 
Reference 
Number Country 
Number of Women 
Starting Depo-Provera For Amenorrhea 
For Excess or 
Irregular Bleeding For All Reasons 
1 year 2 years 1 year 2 years 1 year 2 years 
Dodds 1971 23 Hong Kong 1,883 6 9 13 17 39 52 
Jeppsson 1972 61 Sweden 139 2 14 42 
Khan et al. 1973 76 Paki stan 145 24 24 59 74 
McDaniel & 102 Thailand 
Pardthaisong 1973 
3 month regimen 217a 2 7 40 
6 month regimen 108a 7 10 40 
Scutchfield 154 USA 723 3 14 43 
etal.1971 
Sin et al. 1973 156 Malaysia 550 35 20 59 
Zartman 1970 190 USA 478 4 23 
apostpartum women. Routine estrogen supplement administered after weaning of the infant-usually at 9-12 months . 
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conception was 13 months from the date of the last 150 
mg injection, or 10 months from the assumed end of 
contraceptive protection. By comparison, median time to 
conception after discontinuing IUD or diaphram contracep­
tion is two months. However, by 18 months after discon­
tinuation cumulative conception rates become similar 
regardless of the method previously used (151) (see Fig. 6). 
McDaniel. using 15 weeks after the last injection as the 
discontinuation point, reported that 76 .8 percent of 135 
women were pregnant within one year (97). He compared 
this to one year cumulative conception rates of 94 percent 
for oral contraceptives (142) and 88 percent for IUDs (1 62). 
By 14 months, 82 percent of the former users of Depo­
Provera were pregnant. 
Fertility returns more quickly after Norigest use. Zanartu 
has estimated that conception is likely to occur three to six 
months after the last Norigest injection (182, 183). A study 
of 48 women who discontinued Norigest found that 15, or 
31.3 percent, became pregnant within six months after the 
last injection (74). While a quicker return of fertility may 
make Norigest more acceptable than Depo-Provera for a 
woman who wants more children, it may also mean an 
unplanned pregnancy for a woman who is even a few days 
late receiving her next injection. 
The duration of infertility after discontinuation of Depo­
Provera apparently bears no relationship to the length of 
time the injectable is used (23, 95, 150, 151), but rather 
may reflect individual differences in the rate of drug 
absorption and excretion (151, 174). Women with lower 
body weights tend to conceive sooner after discontinuing 
Depo-Provera (151). 
Suspicion that Depo-Provera may cause permanent infer­
tility has been a major impediment to its wider use. But, 
despite the importance of the issue, little research has 
been conducted on it, possibly because of the difficulty of 
confirming infertility or determining its causes. Thus, it is 
not possible to estimate what percentage of women may 
be affected or even to state firmly that Depo-Provera does 
cause infertility. Ovulation-stimulating drugs have been 
used successfully to return fertility after Depo-Provera 
injections (140), implying that no damage to the reproduc­
tive system had occurred. 
Fetal Effects 
In the late 1950s and early 1960s researchers discovered 
that some progestogens, when given in early pregnancy, 
occaSionally cause masculinization of the external geni­
talia of female fetuses (1, 127, 179). In most of these 
cases, progestogens were given in large doses to prevent 
threatened or habitual abortion. In large doses medroxy­
progesterone acetate (the active ingredient in Depo­
Provera) virilizes rat and rabbit fetuses (107, 127), but no 
such effect on human fetuses has been reported, either 
with doses of Depo-Provera as high as 400 mg (41) or with 
Norigest. 
Recent reports have suggested that in a few women 
steroids administered in early pregnancy may cause con­
genital anomalies. Progestogens administered for preg­
nancy tests are especially implicated (60, 69, 117, 118, 
119, 120). The risk is small-probably no greater than 7 
per 10,000 births (85)-and probably occurs only in con­
junction with "some type of maternal predisposition" (118). 
In an attempt to avoid administration during pregnancy, the 
first injection of Depo-Provera or Norigest is usually given 
withi n a few days after menstruation. 
DEBATE OVER CANCER RISKS 
Suspicion that Depo-Provera might stimulate certain can­
cers has repeatedly delayed approval' of the drug in the 
USA. A controversy over whether the injectable increases 
the incidence of cervical carcinoma in situ, a possible 
precursor of invasive cancer, is still unresolved. Several 
years ago researchers found that both Depo-Provera and 
Norigest produce breast nodules in certain test animals. 
Subsequently, however, many scientists have concluded 
that the results of these animal studies cannot be extrapo­
lated to humans. 
Cervical Carcinoma in Situ 
Some statistics suggest. but do not prove, that cervical 
carcinoma in situ may occur more often among Depo­
Provera users than among nonusers. Among 10,333 
women who used the injectable for a total of 14,891 
woman-years, 35 cases of carcinoma in situ were reported 
(152), but because there was no control group in this 
study, it is difficult to evaluate these data (44). 
An attempt has been made to compare the rates found 
among Depo-Provera users with age and race adjusted 
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Fig. 6. Cumulative conception rates for women who 
discontinued Depo-Provera to become pregnant, com­
pared with cumulative conception rates for former users 
of IUDs and of traditional contraceptives. 
SOURCE : Adapted from Schwallie & Assenza (151). 
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carci noma in situ rates from US surveys conducted by the 
National Cancer Institute (NCI) (152). Such a comparison 
between separate studies, however, leaves a wide margin 
for possible inconsistency and bias. Depending on the age, 
race, location, regimen, and, to a lesser extent. the statisti­
cal method used, rates of cervical carcinoma in situ among 
Depo-Provera users range from less than one to more than 
nine times the age and race adjusted rates in the U.S. 
population (37, 152). For the usual regimen of 150 mg/ 3 
months, the risk is 1.55 times the adjusted US rate (152), a 
difference which is "statistically and clinically insignifi­
cant" (44). 
US FDA officials, faced with the problem of how to interpret 
the inconclusive statistics, twice nearly approved Depo­
Provera for contraceptive use and twice withheld approval 
because of objections from Representative L. H. Fountain, 
chairman of a congressional subcommittee concerned 
with intergovernmental relations. It was Fountain who, 
in 1974, first made an issue of the apparently higher inci­
dence of carcinoma in situ among users of Depo-Provera . 
He has argued that the statistics raise enough doubts 
about the safety of the injectable to justify keeping it off 
the market (37) . 
Responding to Fountain's objections, the USFDA exam­
ined the data, and it concluded that no increased risk could 
be proved. The agency pointed out that almost all of the 
carcinoma in situ cases among Depo-Provera users oc­
curred within the first two years of drug use: 
From all that we know about carcinogenesis, ... such early 
tumors cannot be considered as drug related; the absence 
of a lag time of 3 to 10 years or more is at variance with the 
known toxicological behavior of chemical carcinogens 
(146) 
The USFDA also argued that the statistics about Depo­
Provera raise no more concern than has been raised about 
the possible carcinogenicity of oral steroidal contracep­
tives already marketed with USFDA approval (146, 147). 
Despite these arguments, further protests from Fountain 
led to another postponement of USFDA approval. which, 
as of March 1975, remains in effect. The agency will hold 
an open hearing in April 1975 to discuss the carcinoma in 
situ issue with experts on "contraception, epidemiology, 
and carcinogenesis" (147). 
Only two studies of cervical malignancies among Depo­
Provera users have been conducted with control groups for 
reliable comparisons, and both were too small to be 
statistically significant. A Chilean study found no differ­
ence in the rates at which cervical growths occurred in 
Depo-Provera users and in IUD users. But, for unknown 
reasons, women who chose the injectable were more 
likely to have a cervical malignancy before beginning 
contraception than were those who chose the IUD (18). In a 
Belgian study which included Depo-Provera, abnormalities 
and malignancies, as determined by Papanicoulau cervical 
smears, occurred less than half as often among the users 
of continuous progestogen contraception as in a control 
group using no hormonal contraception (54). 
Papanicoulau smears taken during the Peruvian field trials 
of Norigest produced no evidence that the injectable in-
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creased the incidence of cervico-vaginal abnormalities 
(75) . 
It has been hypothesized that continuous progestogen 
contraception would be more likely to stimulate carcinogen­
esis than cyclical combined estrogen-progestogen con­
traception because an unchanging hormonal environment 
might encourage mutant cells to multiply unchecked, 
whereas a changing hormonal environment might check 
this growth (124, 135). This has not been proved, how­
ever. 
Breast Nodules and Cancer 
Depo-Provera causes breast nodules in beagles. Norigest 
causes breast nodules in rats and mice, as do other 
nortestosterone derivatives. But no evidence suggests that 
the injectable progestogens have the same effect in 
women, and the applicability of the animal study results to 
humans is disputed. 
Studies conducted by the USFDA in the late 1960s found 
that female beagles receiving the body weight equivalent 
of the human contraceptive dose of Depo-Provera devel­
oped persistent breast nodules (175) and beagles receiv­
ing 25 times the equivalent human dose developed malig­
nant nodules and metastases (36). As a result, in 1970 the 
Upjohn Company withdrew from the market Provest, a 
combination oral contraceptive which contained medroxy­
progesterone acetate. Chlormadi none acetate, another 
progesterone derivative studied as an injectable and at the 
time used in some oral contraceptives, was also removed 
from the market because it had a similar effect. The USFDA 
allowed clinical trials of Depo-Provera to continue, how­
ever, reasoning that other effective oral contraceptives were 
available but that Depo-Provera appeared to be the only 
highly effective injectable (8, 36). 
The results of the beagle studies renewed the ongoing 
controversy over the extrapolation of animal study results 
to humans. Some researchers argue that dogs, particularly 
beagles, react differently and are more sensitive to proges­
terone and progestogens than are women and usually 
develop a type of breast nodule rarely found in women (14, 
115, 116, 169, 175). They also point out that primates 
given Depo-Provera have not developed breast nodules, to 
which the USFDA replies that monkeys are more resistant 
to breast nodules than women are (8, 36). 
The only study which compared the incidence of breast 
nodules in Depo-Provera users with incidence in controls 
found no significant difference between the two (98). 
McDaniel, who conducted the study with 1,270 users of 
the injectable and 257 controls, called the beagle experi­
ments "unfortunate and misleading." 
After Norigest was discovered to cause pituitary and breast 
nodules in rats, Schering AG stopped clinical trials (116) 
and removed the injectable from the market in Peru, the 
only country where it was available commercially (25). 
Later studies revealed that in rats Norigest has strong 
estrogenic effects, rather than the progestational effects it 
has in rabbits and humans. Schering scientists postulate 
that this estrogenic effect in rodents causes pituitary 
proliferation and tumors and increases the secretion of 
prolactin by the pituitary. The increased prolactin overstim­
ulates mammary growth and triggers the development of 
mutant cells. Because of species differences this does not 
occur in humans (116). To varying degrees, other nortes­
tosterone derivatives also cause breast nodules in rodents. 
Because rodents appear to be inappropriate test animals, 
the USFDA has been willing to approve for human contra­
ceptive use nortestosterone derivatives which have slight 
tumorigenic effects on rodents. 
USFDA officials defend the agency's general reliance on 
animal studies with the rationale that, while evidence of 
tumorigenic effect in animals does not mean the drug will 
cause tumors in hu mans, evidence that it is not tu morigenic 
in animals allows a drug to be marketed with "a certain 
measure of assurance" of its safety for humans (8). They 
emphasize, however, that the agency's decisions are 
based on US conditions which may not apply in other 
countries: 
The risk-to-benefit principle alone is bound to vary from 
country to country, requiring variations in interpretations of 
results obtained in tests for toxicology, carcinogenicity and 
other mUlti-phased complexities arising from such investi­
gations. Different interpretations and their consequent 
utilization by different agencies in different countries ... 
must be made by the responsible agencies on their merits 
for prevailing conditions and in the best public interest (8). 
PROGRAM ISSUES 
The advantages of injectable progestogens-effectiveness, 
convenience, ease of administration, and lack of inhibition 
of lactation-make them popular with a large number of 
both users and clinicians. Nevertheless, the place of 
injectable progestogens in a comprehensive family plan­
ning program has not yet been fully determined. With 
lactating women or women whose families are complete, 
injectables may be both popular and appropriate, but, from 
the program planner's point of view, the overall effect 
could be the substitution of injectables for IUDs or sterili­
zations. With nulliparous women or those who want more 
children, many family planning officials still urge caution 
and limit the use of injectables. 
Advantages. 
From the users point of view, injectables are attractive. 
Reports from family planning programs around the world 
show that, where women were offered a choice among 
contraceptive methods which included an injectable, be­
tween one-quarter and three-quarters chose the injectable 
(51, 74, 90, 125, 155, 172). Effectiveness, convenience, 
freedom from fear of forgetting (94), and the fact that 
husbands cannot interfere with its use (125) are major 
reasons for the popularity of the injectable (see Fig. 7). The 
mode of administration is also an asset. The attitude 
McDaniel and Pardthaisong found in Thailand holds true 
elsewhere as well (17, 51, 136): 
Fig. 7. Advantages and Disadvantages of Injectable 
Progestogens Compared to Oral Contraceptives and IUDs. 
Advantages of Injectables Advantages of Injectables 

Compared to Orals Compared to IUDs 

• 	 More convenient to use. No • More effective. 
dailY pill taking . 
• 	 No pelvic examination or in­
• 	 Freedom from fear of forget­ sertion procedure necessary . 
ting. 
• 	 No risk of IUD side effects 
• 	 No inhibition of lactation. such as pain, perforations, or 
infections. 
• 	 No estrogen side effects or 
possible long-term hazards of • Heavy bleeding less frequent . 
estrogen . 
• 	 Husband cannot interfere 
with use. 
Disadvantages of I njectables Disadvantages of Injectables 

Compared to Orals Compared to IUDs 

• 	 Cannot be immediately with­ • Need to return periodically 
drawn if harmful or distress­ for injections. 
ing side effects occur. 
• 	Possibil ity of disturbed men­
• 	 Greater possibility of dis­ strual patterns. 
turbed menstrual patterns. 
• 	Possible delay in return of 
• 	 Possible delay in return of fertility . 
fertility. 
• Carcinogenic issues still un­
• 	 Self-administration not prac­ resolved. 
tical . 
. .. since the turn of the century, medicines given by 
needle and syringe have been widely regarded as more 
reliable, more effective, and more prompt in their actions 
than medicines taken orally. In the minds of many of the 
common people, a physician without a syringe is not a real 
physician at all , no matter how high his degree or other 
qualifications may be. Therefore a contraceptive to be taken 
by injection has a tremendous advantage over other meth­
ods (95). 
An important advantage is that injectables do not inhibit 
lactation (43, 65, 183), as the estrogen-progestogen oral 
contraceptives sometimes do (10, 79, 82). In fact, the 
injectables may actually increase both the duration of 
lactation (43, 45) and the volume of milk (47, 65, 80). They 
are therefore preferable to oral contraceptives for postpar­
tum use, especially in countries where mothers breastfeed 
their children for long periods (47). 
An effective steroidal contraceptive which does not reduce 
lactation is welcome for two reasons. Firstly, in the post­
partum period women are highly motivated to accept 
contraception (191 , 192). Secondly, contrary to popular 
thought, ovulation and conception can occur before the 
end of lactation amenorrhea (170). Furthermore, in areas 
where a woman 's only access to medical care and advice 
is during childbirth, a single injection at that time can 
provide her with several months of protection against the 
next pregnancy (76). In an extensive review of the duration 
and contraceptive effect of lactation, Dr. Franz Rosa of the 
UN Fund for Population Activities (UNFPA) has recom­
mended that progestogen-only contraceptives be provided 
to lactating women at least until menstruation recom­
mences (138) . 
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Whether injectable progestogens alter the composition of 
breast milk is uncertain. While one research group found 
no significant differences in specific gravity, protein con­
tent, and fat content between the milk of Depo-Provera 
users and that of controls (80), another group reported 
significantly higher milk protein levels and decreased milk 
lipid and lactose levels (47). The injectable progestogens 
apparently do not affect the immunologic powers of breast 
milk (27). 
Depo-Provera and/or its by-products (metabolites) can be 
found in the breast milk of women using the injectable 
(78), but whether this can affect an infant has not been 
determined. Radioimmunoassays, used to test for the 
presence of steroids in breast milk, cannot distinguish 
between the drug and its metabolites, and it is not known 
whether the metabolites are physiologically active. There 
have been no clinical reports of adverse effects on infants 
whose mothers were receivi ng progestogens, but addi­
tional research is needed on this point. 
In a family planning program injectables offer the advan­
tage of quick, easy, and infrequent administration. McDan­
iel has found that, if a woman returning for an injection 
has no complaints, she can be processed in 60 to 90 
seconds. This includes time for a short interview with a 
d()~lor or nurse-midwife, paperwork, and the injection 
itself (95). Dispensing both Depo-Provera and oral contra­
ceptives, one of McCormick Hospital's mobile family plan­
ning clinics routinely serves 800 women in one day and 
1,500 in the next on two stops near Thailand's border with 
Burma (93) (see Fig. 8). The six-month regimen saves even 
more clinic time and resources, but it provides a woman 
less contact with health personnel should questions or 
problems arise. 
The injectable progestogens can be administered by jet 
injector (126, 143), and evidence from animal studies 
indicates that use of the jet may reduce the variation from 
one woman to the next in the return of fertility after 
discontinuation (177). Both Depo-Provera and Norigest 
can be stored without refrigeration for up to five years. 
Like oral contraceptives, the injectables have a great 
potential for wider distribution and use. Paramedical per­
sonnel can easily give injections. Dropping the require­
ment that a woman have a pelvic examination before 
starting an injectable would also broaden its acceptance in 
many areas, since some women will refuse to seek contra­
ception if pelvic or general physical exams are required 
(86, 139). In developing countries the benefits of wider 
distribution of both injectable and oral contraceptives, 
especially in terms of the potential reduction expected in 
maternal mortality rates, outweigh the risks (139) (see 
Population Report A-2). For these reasons McDaniel does 
not require pelvic exams in his Thailand program. 
We feel that furnishing family planning services to a large 
number of women, without the ··Iuxuries·· of general 
physical and pelvic examinations and cancer detection, is 
more important and fruitful than serving a few, and discour­
aging many, in an attempt to cling too rigidly to more 
academic and professional medical standards (91). 
Fig. 8. Women receive numbered tickets to wait in turn 
for Depo-Provera injections or oral contraceptives from 
a McCormick Hospital mobile clinic in Chiang Mai Pro­
vince, Thailand. (Courtesy of Dr. E. B. McDaniel.) 
... But Use Restricted 
Despite the advantages of injectables, many family plan­
ning officials have been reluctant to permit the unre­
stricted use of Depo-Provera. They have been concerned 
because the drug could not be withdrawn quickly if a 
problem arose, although this has not proved a problem in 
actual practice (94). More importantly, they have feared 
that Depo-Provera might cause permanent infertility. 
There has been no proof that i njectables can cause steril­
ity, and, if they do, it occurs very rarely. But officials and 
clinicians are aware not only that undesired infertility 
could have disastrous emotional and social consequences 
for the woman involved, but also that the reputation of a 
family planning program and of family planning itself could 
be ruined if people thought they had been deceived about 
the reversibility of the method. Thus, even in countries 
such as Jamaica, Malaysia, and Thailand, where Depo­
Provera is now offered through national family planning 
programs, restrictions have been placed on its use. In 
Jamaica, only women whose families are complete may 
obtain Depo-Provera. The World Health Organization 
(WHO) has imposed the same restriction on Depo-Provera 
supplied by UNFPA. The International Planned Parenthood 
Federation (IPPF), though still without an official policy, 
unofficially advises its affiliates against giving Depo­
Provera to young women with few children (139). In 
Nairobi, the Family Welfare Center, which obtains Depo­
Provera from IPPF, restricts the injectable to women over 
30 with five or more children and to those who, with their 
husbands, sign consent forms (51). 
In the Thai National Family Planning Program, a woman 
using Depo-Provera must have at least two living children 
and want no more. If, after using the injectable for ·'a 
period of time," she still wants no more children, she will 
be urged to discontinue the injectable and to accept 
sterilization. The Thai National Ministry of Health hopes 
that Depo-Provera, a recent addition to the national pro­
gram, will attract new participants to family planning 
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Table 5-Usage of Depo-Provera Reported by Family Planning Associations Supplied 

by the International Planned Parenthood Federation, 1971-74, and Planned IPPF Deliveries, 1975 

Region Usage 1971 Usage 1972 Usage 1973 Estimated Usage 1974 To Be Delivered 1975 
Africa 7,140 22,526 106,768 129,130 241,000 
Indian Ocean 2,128 9,157 13,030 38,360 77,000 
Middle East & North Africa 0 100a 4,055 7,000 13,000 
South East Asia & Oceania 28,460b 53,300c 83,017 161,874 177 ,000 
Western Hemisphere 20,331 22,421 35,382 45,932 114,100 
Western Pacified 21,519 23,338 23,082 18,000 18,000 
TOTAL 79,578 130,842c 265,334 400,296 640,100 
aSudan only. bThailand only. cApproximate. d Hong Kong only. 
SOURCES: IPPF Reports to Donors (56,57,58l. 
rather than draw women away from sterilization proce­
dures, the number of which has been rapidly increasing 
recently. Depo-Provera is currently available only at Na­
tional Family Planning Program hospitals and health cen­
ters staffed by physicians-some 300 out of about 4,000 
program outlets (180). However, a study has been started 
to evaluate the use of auxiliary midwives to prescribe and 
administer the drug. 
The McCormick Hospital program in Chiang Mai, Thailand, 
which was one of the first to offer Depo-Provera, takes a 
less stringent approach. The only requirement for new 
acceptors of Depo-Provera is that they have demonstrated 
their fertility by a previous pregnancy. McDaniel, who 
directs the program, reports that this requirement "is only 
to protect the reputation of the program from the acci­
dental giving of Depo-Provera to an already sterile couple" 
(94). 
In Malaysia national family planning officials also have 
restricted Depo-Provera. The injectable is available 
through 10 National Family Planning Board (NFPB) clinics 
with attending medical officers to women who have "al­
ready demonstrated their fertility" and have completed 
their families. The NFPB requires that women receive 
physical and pelvic examinations before starting Depo­
Provera and checks for breast nodules with every injection. 
Also, they must be told individually about all possible side 
effects, including menstrual cycle disruption and "possible 
infertility" (132). 
Had USFDA approval of Depo-Provera gone into effect, it 
would have placed special requirements on the use of the 
injectable in the USA. I n its approval statement the agency 
wrote that Depo-Provera was intended for "those patients 
in need of contraception who cannot accept more regi­
mented methods or in whom other alternatives are either 
contraindicated, unreliable, or otherwise unacceptable ." 
Before a woman could have received her first injection, 
she would have had to give her consent after reading a 
brochure which explained the known and suspected side 
effects and risks of Depo-Provera . Also, pharmacies, pri­
vate doctors, and family planning clinics would have been 
required to report back to the Upjohn Company on their 
distribution or use of Depo-Provera. If harmful effects were 
later discovered, the company then would have been able 
to notify doctors, who in turn would have contacted their 
patients (146). Because USFDA approval never took effect, 
these requirements were never instituted. 
Fig. 9. Partial List of Countries 

Where Depo-Provera is Available as a Contraceptive 

Through Commercial Channels and/or 

Family Planning Programs, 1974-1975 

Some countries where Depo·Provera for contraception is 
available: 
Western Hemisphere: 
Argentina Grenada Peru 
Barbados Guatemala St. Kitts 
Bolivia Honduras St. Lucia 
Chile Jamaica St . Vincent 
Colombia Mexico Surinam 
Costa Rica Panama Trinidad 
EI Salvador Paraguay 
Middle East & Africa: 
Afghanistan Lebanon Seychelles 
Botswana Liberia Sierra Leone 
Egypt Leso tho South Africa 
Gambia Malagasy Sudan 
Ghana Mauritius Tanzania 
Iraq Nigeria Tun isia 
Iran Rhodesia Uganda 
Kenya Saudi Arabia 
Far East, South Asia & Pacific: 
Bangladesh Malaysia Philippines 
Hong Kong New Zealand Pakistan 
Indonesia Sabah Thailand 
Khmer Republic Sarawak Vietnam 
Korea Sri Lanka 
Europe: 
Belgium Federal Republic of Netherlands 
Denmark Germany Spain 
Some countries where Depo·Provera for contraception is not 
available: 
Brazil Japan United States 
Canada Sweden Venezuela 
India United Kingdom 
SOURCES: Heywood (49,50); IPPF (58); Nortman & Hof· 
statter (116). 
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DISTRIBUTION 
Despite caution and restr ictions on Depo-Provera, its use 
has grown in recent years . At least 10 countries now offer 
the injectable in their national family planning programs, 
and use for contraceptive purposes has been approved in 
64 countries. Two international donor organizations, IPPF 
and UNFPA, now supply Depo-Provera, but the US Agency 
for International Development (USAID) does not. since it 
does not supply drugs which have not been approved by 
the USFDA for use in the USA. 
IPPF is currently the largest international supplier of 
injectable contraception . In 1975 IPPF plans to provide 
approximately 640,000 three-month doses of Depo­
Provera to family planning clinics in 41 countries (58) . This 
could provide one year of contraception for almost 
150,000 women (124). Requests to IPPF for Depo-Provera 
have grown rapidly over the past several years, both in 
terms of the number of programs requesting the injectable 
and the amounts requested (see Table 5). The largest IPPF 
shipments in 1974 went to Thailand (140,000 three­
month doses), Sri Lanka (35,000 doses), Uganda (12,000 
doses), Kenya and Costa Rica (10,000 doses each) (58) . 
UNFPA began supplying small quantities of Depo-Provera 
in 1972. In 1972 and 1973 UNFPA shipments ranged from 
220 to 10,000 doses and went to six countries (19). In 
1974, at a cost of $.71 (US) per three-month dose, UNFPA 
ordered $200,000 (US) worth of Depo-Provera for Thai ­
land, $38,000 (US) worth for Jamaica, and $600,000 (US) 
worth to be turned over to IPPF for distribution to its 
affiliates (19, 137). 
UNFPA has set aside a small portion of its 1975 contracep­
tive supplies budget-up to $200,000 (US) out of almost 
$4 million-to buy either Depo-Provera or, if WHO gives its 
approval, Noristerat (Norigest), depending upon which 
manufacturer submits the lower bid price. 
The Swedish International Development Authority (SIDA) 
has supplied injectable contraception only once, and it 
does not plan to do so again because of reservations about 
side effects. In 1974 SIDA provided 100,000 three-month 
doses of Depo-Provera to Malaysia 's national family plan­
ning program (164). In 1975 and coming years, the Malay­
sia National Family Planning Board intends to obtain its 
supply of injectables from UNFPA (132) 
National family planning programs which offer Depo­
Provera include those in Jamaica, Guatemala, Thailand, 
Malaysia, Hong Kong, Khmer Republic (Cambodia). Bot­
swana, South Africa, Rhodesia, and Uganda . The fees for 
injections which these programs charge to users vary. In 
Jamaica, for example, injections, like all other contracep­
tive supplies, are free . In Hong Kong in 1974 the fee 
ranged from no charge to $1.40 (US) per injection, depend­
ing on ability to pay. Other fees per injection in 1974, 
expressed in US dollars, included : Botswana , $.43 ; Gua­
temala , $.50; Khmer Republic, $.30; Rhodesia , $.41; and 
Uganda, $ .70 (121). The new Thai pilot program charges a 
service fee of $ .75 for each injection, as does the McCor­
mick Hospital program (94). 
Total Depo-Provera Sales 
Through commercial channels and sales to international 
donors, the Upjohn Company has sold close to 11 million 
doses of Depo-Provera since 1968. The company's Belg ian 
affiliate, Upjohn S. A. Purrs, manufactures the drug for 
international distribution . Upjohn affiliates in Colombia, 
Mexico, Korea, the Philippines, South Africa, and Argen­
tina produce Depo-Provera for use within their own coun­
tries but do not ship to other nations. The drug is now com­
mercially available as a "contraceptive," "anovulatory 
agent," or "anti -conception compound" in 64 nations, 
including 19 Western Hemisphere countries, 13 Middle 
East countries, 17 African, 8 European, and 7 Far East 
countries (49) (see Fig. 9). 
Though doubts have clouded the history of injectable 
progestogens and important questions remain unan­
swered, use of Depo-Provera has grown in recent years . 
Barring conclusive proof that the injectables cause cancer, 
their use probably will continue growing . In fact. injec­
tables may become the first cont raceptives produced by 
modern technology to win acceptance in the developing 
countries while lacking approval in most major industrial­
ized nations. 
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